During their operations, they incurred losses of about 220 million dollars. The corporation was also criticized for some design elements of its clinical trials related to the need to perform critical care and resuscitation while patients were in grave clinical conditions due to the mechanisms of injury incurred and the consequent inability of patients to provide informed consent for treatment.
During their operations, they incurred financial losses of approximately 220 million dollars. The corporation faced criticism for some aspects of its clinical trials involving critical care and resuscitation in severe medical conditions caused by injury mechanisms and the patients' lack of ability to give informed consent.